Watchlist Price Alert

Castle Biosciences Inc. (CSTL)

NASDAQ: CSTL · Real-Time Price · USD

18.73

-0.62 (-3.20%)

At close: May 05, 2025, 3:59 PM

17.48

-6.65%

Pre-market: May 06, 2025, 04:58 AM EDT

-3.20% (1D)

Bid	17.29
Market Cap	540.12M
Revenue (ttm)	332.07M
Net Income (ttm)	18.25M
EPS (ttm)	0.62
PE Ratio (ttm)	30.2
Forward PE	-10.92
Analyst	Strong Buy

Ask	19.9
Volume	385,415
Avg. Volume (20D)	435,273
Open	19.40
Previous Close	19.35
Day's Range	18.69 - 19.24
52-Week Range	16.96 - 35.84
Beta	1.19

About CSTL

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients w...

Sector Healthcare

IPO Date Jul 25, 2019

Employees 761

Stock Exchange NASDAQ

Ticker Symbol CSTL

Website https://castlebiosciences.com

Full Company Profile

Analyst Forecast

According to 7 analyst ratings, the average rating for CSTL stock is "Strong Buy." The 12-month stock price forecast is $40, which is an increase of 113.62% from the latest price.

Stock Forecasts

Earnings Surprise

New

Castle Biosciences has released their quartely earnings on May 5, 2025:

Revenue of $88M exceeds estimates by $7.62M, with 20.59% YoY growth.

EPS of -0.2 misses estimates by -0.13, with -122.22% YoY decline.

Why Price Moved

2 months ago

-14.24%

Castle Biosciences shares are trading lower. The c... Unlock content with Pro Subscription

3 months ago

-13.55%

Castle Biosciences shares are trading lower after the company reported preliminary FY24 financial results.

News

Just now · seekingalpha.com

Castle Biosciences, Inc. (CSTL) Q1 2025 Earnings Call Transcript

Castle Biosciences, Inc. (NASDAQ:CSTL ) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Camilla Zuckero - Vice President of Investor Relations and Corporate Affairs Derek ...

1 day ago · zacks.com

Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates

Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.09 per share a year ago.

2 months ago · businesswire.com

New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will share new data on its DecisionDx-Melanoma and DecisionDx-SCC tests for patients with skin cancers at the 2025 AAD Annual Meeting.

2 months ago · seekingalpha.com

Castle Biosciences, Inc. (CSTL) Q4 2024 Earnings Call Transcript

Castle Biosciences, Inc. (NASDAQ:CSTL ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Camilla Zuckero - VP, IR and Corporate Affairs Derek Maetzold - Founder, Pres...

2 months ago · zacks.com

Castle Biosciences, Inc. (CSTL) Surpasses Q4 Earnings and Revenue Estimates

Castle Biosciences, Inc. (CSTL) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to loss of $0.10 per share a year ago.

2 months ago · businesswire.com

Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #diagnostics--Castle Biosciences, Inc. (Nasdaq: CSTL), today announced its financial results for the fourth quarter and year ended December 31, 2024.

2 months ago · businesswire.com

Castle Biosciences to Participate in Upcoming Investor Conferences

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences' executive management is scheduled to present a company overview at two investor conferences next month.

2 months ago · zacks.com

CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know

Castle Biosciences' fourth-quarter 2024 earnings are likely to have gained from higher test volume growth of its dermatologic and non-dermatologic tests.

2 months ago · zacks.com

Castle Biosciences, Inc. (CSTL) Reports Next Week: Wall Street Expects Earnings Growth

Castle Biosciences (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago · zacks.com

Wall Street Analysts See a 50.79% Upside in Castle Biosciences (CSTL): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 50.8% in Castle Biosciences (CSTL). While the effectiveness of this highly sought-after metric is questionable,...

Load More News